A Phase 2 Study of BA3011 Alone and in Combination With PD-1 Inhibitor in Adult Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor, EGFR, or ALK Inhibitor
Latest Information Update: 26 Jul 2024
At a glance
- Drugs Mecbotamab vedotin (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors BioAtla
- 25 Jul 2024 Results presented in the BioAtla Media Release.
- 26 Mar 2024 According to a BioAtla media release, Enrolled 33 target-agnostic patients at the 2Q3W regimen across squamous and non-squamous patients, Study is on track to evaluate initial clinical benefit in the target-agnostic non-squamous EGFR wild-type patient population in 2Q 2024
- 05 Dec 2023 According to a BioAtla media release, data from this study were presented at the IASLC Conference December 1-3 and at a virtual KOL Event held December 4, 2023.